<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/42C04D5B-4391-45A4-8CB8-813679646FF1"><gtr:id>42C04D5B-4391-45A4-8CB8-813679646FF1</gtr:id><gtr:firstName>Susanna</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Dunachie</gtr:surname><gtr:orcidId>0000-0001-5665-6293</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G84%2F6323"><gtr:id>FD1DA548-7C5B-4D51-87C6-91211744B2CB</gtr:id><gtr:title>Gene Expression Profiling for the Elucidation of New Correlates of Protective Immunity Against Plasmodium falciparum</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G84/6323</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>139428</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Starter Grants for Clinical Lecturers</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Academy of Medical Sciences (AMS)</gtr:fundingOrg><gtr:id>5D3C2DDF-00A6-4358-9B17-5AA8CF2B236A</gtr:id><gtr:outcomeId>rRZXx3LK4sY0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IDSA Young International Investigator Award/Infectious Diseases Society of America</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Infectious Diseases Society of America</gtr:fundingOrg><gtr:id>ED903B62-AAD9-4F05-BE38-B0AFDA3E1A49</gtr:id><gtr:outcomeId>FkEFajVtBfz0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>173F227E-F350-44CA-891A-31D12890BA13</gtr:id><gtr:title>Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37b6c85a38f01f06523f07091de5c453"><gtr:id>37b6c85a38f01f06523f07091de5c453</gtr:id><gtr:otherNames>Keating SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15392_12_16237057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6306BB-958E-45B2-8323-47C2F0698220</gtr:id><gtr:title>Profiling the host response to malaria vaccination and malaria challenge.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fa0aa0eeb8995cacee40892c497412"><gtr:id>74fa0aa0eeb8995cacee40892c497412</gtr:id><gtr:otherNames>Dunachie S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5898f6cee40321.07684172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2589ED37-A365-4057-8966-D9E11975669A</gtr:id><gtr:title>Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/418f248c313956883eafb2fe6ad99932"><gtr:id>418f248c313956883eafb2fe6ad99932</gtr:id><gtr:otherNames>Webster DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15392_12_16488059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CA7EC5-CD2C-4136-B3DC-B19409EC1244</gtr:id><gtr:title>Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9220bd722f843e0dac27ddc9068ac50c"><gtr:id>9220bd722f843e0dac27ddc9068ac50c</gtr:id><gtr:otherNames>Walther M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15392_12_15603885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AA3CFC5-7190-4706-B3A6-26027E39E918</gtr:id><gtr:title>Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c84a57e2de07c209dc3eb51a68b9fb94"><gtr:id>c84a57e2de07c209dc3eb51a68b9fb94</gtr:id><gtr:otherNames>Fletcher HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5898f7f2ce9b11.85934062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E58E9E8-7446-40A8-8123-8B81431D43E5</gtr:id><gtr:title>A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a3099440500bd9c829d5a0e994effa"><gtr:id>f4a3099440500bd9c829d5a0e994effa</gtr:id><gtr:otherNames>Dunachie SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>pm_15392_12_16988273</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842C383C-6FA0-429B-8BCA-88032BA6BF8A</gtr:id><gtr:title>Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9220bd722f843e0dac27ddc9068ac50c"><gtr:id>9220bd722f843e0dac27ddc9068ac50c</gtr:id><gtr:otherNames>Walther M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>pm_15392_12_16622207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30C07AD5-1987-4493-8AD0-7201776116CA</gtr:id><gtr:title>MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da7b7941ef60f7b1128915d47c8c2a9"><gtr:id>3da7b7941ef60f7b1128915d47c8c2a9</gtr:id><gtr:otherNames>Berthoud TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>5898f7f2a05b20.76871268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8351224A-092A-471F-B619-D56A8A9079E7</gtr:id><gtr:title>Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/418f248c313956883eafb2fe6ad99932"><gtr:id>418f248c313956883eafb2fe6ad99932</gtr:id><gtr:otherNames>Webster DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_15392_12_15781866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1BBECC-D62F-4CB0-A146-296AE8D27F87</gtr:id><gtr:title>Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/329199d4f94b2533cf3284557ba947c2"><gtr:id>329199d4f94b2533cf3284557ba947c2</gtr:id><gtr:otherNames>Andrews L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>pm_15392_12_16014857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE0BC57F-EC49-47A0-A945-36A623AD6091</gtr:id><gtr:title>Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54f8f1b095af093fc13bb1544b6f0cfe"><gtr:id>54f8f1b095af093fc13bb1544b6f0cfe</gtr:id><gtr:otherNames>Vuola JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15392_12_15611270</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71691A52-111C-4471-8680-FD5AF35113EC</gtr:id><gtr:title>Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/278dacd0884f78b1a4587476a0967f3b"><gtr:id>278dacd0884f78b1a4587476a0967f3b</gtr:id><gtr:otherNames>Mwacharo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5898f7f24164e8.43215326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF1DA1C2-7FE7-4D8C-99B6-79DEF53BBFA7</gtr:id><gtr:title>MIG and the regulatory cytokines IL-10 and TGF-?1 correlate with malaria vaccine immunogenicity and efficacy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a3099440500bd9c829d5a0e994effa"><gtr:id>f4a3099440500bd9c829d5a0e994effa</gtr:id><gtr:otherNames>Dunachie SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5898f7f26d1488.27459014</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96803395-EF78-4104-9FEA-5691A9DB1920</gtr:id><gtr:title>Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9220bd722f843e0dac27ddc9068ac50c"><gtr:id>9220bd722f843e0dac27ddc9068ac50c</gtr:id><gtr:otherNames>Walther M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>pm_15392_12_16169501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>660C2640-6C16-4A94-B38E-46389122B1A5</gtr:id><gtr:title>A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4a3099440500bd9c829d5a0e994effa"><gtr:id>f4a3099440500bd9c829d5a0e994effa</gtr:id><gtr:otherNames>Dunachie SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15392_12_16434127</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8270781F-2950-4E5F-9414-B07EBF86F480</gtr:id><gtr:title>Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fa0aa0eeb8995cacee40892c497412"><gtr:id>74fa0aa0eeb8995cacee40892c497412</gtr:id><gtr:otherNames>Dunachie S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5675e9fc347d7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79F63B37-68FA-45CD-B487-9E7E377F9C55</gtr:id><gtr:title>Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/080d9c77d9089737ba36e6a808316bf7"><gtr:id>080d9c77d9089737ba36e6a808316bf7</gtr:id><gtr:otherNames>Bejon P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_15392_12_15655787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A888AC8-5206-4A08-8D19-DEBFD142CAE0</gtr:id><gtr:title>Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-na&amp;iuml;ve and malaria-exposed individuals.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/080d9c77d9089737ba36e6a808316bf7"><gtr:id>080d9c77d9089737ba36e6a808316bf7</gtr:id><gtr:otherNames>Bejon P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>pm_15392_12_16966412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E93FA69-0F8F-4849-BB37-665863BC9537</gtr:id><gtr:title>Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eed120722c68b490adeddd52dfc898c"><gtr:id>3eed120722c68b490adeddd52dfc898c</gtr:id><gtr:otherNames>Thompson FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15392_12_18231580</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G84/6323</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>